Domestic pharmaceutical companies are releasing a new form of Donepezil, a component of dementia treatment, but existing low-cost drugs are acting as a dilemma. Donepezil accounts for about 80% of dementia treatments, so competition among the same products is fierce. As there are 150 pharmaceutical companies with the same ingredient products, the drug price is breaking the lowest price every time.

According to the industry on the 7th, Hyundai's Donepezil, Hypezil Powder 5mg, has been applied to the market since this month. This product is expected to be useful for patients who have difficulty swallowing existing tablets because it can be taken in water. The upper limit is 1,700 won. The MFDS recognized